Weight Loss for Three Body Types

Lilly, Weight Loss and Experimental

Patients On Lilly’s Experimental Diabetes Drug Lost 15% Of Their Weight And Lowered Blood Sugar, Company Says

After 40 weeks, the highest dose of Retatrutide helped patients lose 15.3% of their body weight—for an average of 33.3 pounds for each participant.

· 1d

Lilly’s Experimental Diabetes Drug Shows Promise for Weight Loss

· 1d

Eli Lilly’s retatrutide cuts weight 17% in diabetes trial

· 1d

Eli Lilly’s retatrutide shows efficacy for diabetes, weight management

Eli Lilly's next generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight without a plateau, the company announced.

· 1d

Eli Lilly’s next-generation obesity drug delivers strong results in late-stage trial

· 1d

Lilly’s triple G agonist succeeds in Phase III diabetes trial

Everyday Health on MSN

New Kind of Diabetes Drug Helped People Lower Blood Sugar and Lose Almost 40 Pounds

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

14d

Do Ozempic and Similar Weight Loss Drugs Work for Everyone? New Study Has Answers

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and baseline health measures.

Healio

Retatrutide confers reductions in HbA1c, body weight for adults with type 2 diabetes

A GIP/GLP-1/glucagon triple agonist reduced HbA1c by up to 1.9 percentage points at 40 weeks for adults with type 2 diabetes, according to topline results from the TRANSCEND-T2D-1 trial. Retatrutide (Eli Lilly) is a once-weekly injectable medication currently under investigation to treat type 2 diabetes,

Medical News Today

Almost half of those stopping GLP-1 weight-loss drugs keep the weight off

A new study suggests that almost half of people stopping GLP-1 weight-loss drugs may keep the weight off. However, many of these people continued other forms of treatment after stopping GLP-1 drugs.

9hon MSN

Weight-loss drugs are changing the way people dress. These companies stand to benefit.

As GLP-1 users lose weight, they’ll likely be shopping for clothes in new sizes, translating into up to $13 billion a year in additional spending in the U.S., Bernstein analysts said.